Abstract:PURPOSE:Anti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside. There is no effective clinical strategy targeting vasculogenic mimicry, yet. We show here that CD146 is a novel target to inhibit uveal melanoma progression since it regulates both uveal melanoma angiogenesis and vasculogenic mimicry activity.METHODS:CD146 inhibition was achieved with its specific siRNAs or antibody AA98. Tube formation and migration of primary human retinal microvascular endothelial cells and tube-like structure formation, migration, invasion of uveal melanoma cells were evaluated after CD146 inhibition. The underlying mechanisms were investigated by Western blot and immunofluorescence. Finally, uveal melanoma cells were injected subretinally into the eyes of nude mice and AA98 was administrated. Tumor size was revealed by H&E staining, and angiogenesis and vasculogenic mimicry were evaluated with CD31-PAS staining.RESULTS:CD146 inhibition induced declines in tube formation and migration of primary human retinal microvascular endothelial cells and tube-like structure formation of uveal melanoma cells. CD146 mediated VEGFR/AKT/p38/NF-κB and FAK/VE-cadherin signal cascades were partially responsible for these biological effects. CD146 blockade by siRNA or AA98 also resulted in inhibition of migration and invasion as well as EMT process of uveal melanoma cells. The physiological relevance of such declines was confirmed by showing that AA98 treatment markedly suppressed the tumor growth, angiogenesis and vasculogenic mimicry induced by implantation of uveal melanoma cells into the eyes of nude mice.CONCLUSIONS:CD146 is a novel mediator of both angiogenesis and vasculogenic mimicry in uveal melanoma. Its antibody AA98 has the potency to be developed as a new antibody drug for treating uveal melanoma. Our results warrant further assessment of CD146 as a potential target to improve therapeutic management of uveal melanoma in a clinical setting.

Cd146 Is A Coreceptor For Vegfr-2 In Tumor Angiogenesis

Neuropilin-2–Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma

Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice

Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition

Endothelial CD146 is Required for in Vitro Tumor-Induced Angiogenesis: the Role of a Disulfide Bond in Signaling and Dimerization

CD146 is required for VEGF-C-induced lymphatic sprouting during lymphangiogenesis

Inhibition of CD146 Lessens Uveal Melanoma Progression Through Reducing Angiogenesis and Vasculogenic Mimicry.

MicroRNA 329 suppresses angiogenesis by targeting CD146.

CD146 Acts As a Novel Receptor for Netrin-1 in Promoting Angiogenesis and Vascular Development.

Targeting Endothelial CD146 Attenuates Colitis and Prevents Colitis-Associated Carcinogenesis.

CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer.

CD146 contributes the metastatic properties and antitumor immunity of human colon adenocarcinoma cells

DCBLD1 Modulates Angiogenesis by Regulation of the VEGFR-2 Endocytosis in Endothelial Cells

NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction.

Erratum to: CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases

Soluble CD146 cooperates with VEGF-A to generate an immunosuppressive microenvironment in CD146-positive tumors: interest of a combined antibody-based therapy

VEGFR2 Regulates Endothelial Differentiation of Colon Cancer Cells

Upregulation of HAb18G/CD147 in Activated Human Umbilical Vein Endothelial Cells Enhances the Angiogenesis

Targeting CD147 is a Novel Strategy for Antitumor Therapy

DCBLD1 modulates angiogenesis by regulating of the VEGFR-2 endocytosis in endothelial cells

Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth